People: Eli Lilly and Co (LLY.N)
24 Feb 2017
Mr. David A. Ricks has been appointed as Chairman of the Board, President, Chief Executive Officer of the Company. He has been appointed as President, Chief Executive Officer, Director effective January 1, 2017 and chairman of the board effective June 1, 2017. Mr. Ricks formerly was general manager of Lilly affiliates in China and Canada. Ricks' responsibilities will include the U.S., Japan, and Europe. Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal, and urology. He is a 15-year Lilly veteran, has led three of Lilly's important affiliates: the U.S., China, and Canada. As president of Lilly USA since 2009, Ricks spearheaded a new operating model focused on customer satisfaction and revenue growth while preparing for patent losses and changes to the health care system in the United States. He joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving into key international roles for seven years - as president and general manager of Lilly's affiliate in China, one of the world's fastest-growing pharmaceutical markets. He previously served as general manager of Lilly Canada after roles there as director of pharmaceutical marketing and national sales director. He earned a bachelor's degree in business from Purdue University and an MBA from Indiana University. Prior to joining Lilly, he held positions with Hewlett-Packard Corp. and IBM.
|Total Annual Compensation,||--|
|Restricted Stock Awards,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|